Endocrine therapy is an important way of breast cancer treatment, and estrogen receptor or progesterone receptor positive breast cancer patients should use endocrine therapy after surgery as follows: 1. The main drug treatment modalities used in premenopausal women are tamoxifen drug, toremifene drug, etc., and the endocrine treatment modalities for breast cancer in postmenopausal women mainly include AI agents, such as exemestane, anastrozole, letrozole, etc.; 2, Another way of endocrine treatment is ovarian function denervation, and the denervation methods mainly include drug denervation and surgical denervation. Drugs are more commonly used in the clinic as OFS drugs, including leuprolide and goserelin. Surgical ovarian denervation endocrine therapy, before the invention of drug ovarian denervation, mainly through surgical ovarian denervation, including surgical resection of the ovaries, laparoscopic oophorectomy, to achieve the role of ovarian denervation endocrine therapy; 3, SERM drugs, belonging to the estrogen and progesterone receptor antagonists, including fulvestrant, in recent years, mainly used in the middle and late stage of hormone receptor positive breast cancer patients. Hormone receptor positive appear metastasis and recurrence, mainly take SERM class drug fulvestrant for endocrine treatment. In summary, endocrine treatment modalities mainly include premenopausal use of moxifene and toremifene, postmenopausal use of mainly AI-type drugs, such as exemestane, letrozole, anastrozole, or SERM-type drugs, such as fulvestrant, as well as ovarian function debulking, including surgical debulking and OFS drug debulking.